Henry Schein downgraded by Robert W. Baird with a new price target
$HSIC
Medical Specialities
Health Care
Robert W. Baird downgraded Henry Schein from Outperform to Neutral and set a new price target of $72.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/26/2025 | $83.00 | In-line → Outperform | Evercore ISI |
| 7/25/2025 | $75.00 | Buy → Hold | Stifel |
| 7/14/2025 | $72.00 | Outperform → Neutral | Robert W. Baird |
| 2/14/2025 | $80.00 | Equal Weight | Wells Fargo |
| 1/6/2025 | $69.00 → $84.00 | Underperform → Buy | BofA Securities |
| 12/4/2024 | $75.00 | Neutral | Mizuho |
| 7/22/2024 | $81.00 → $92.00 | Neutral → Outperform | Robert W. Baird |
| 2/26/2024 | $78.00 | Market Perform | Leerink Partners |
10-Q - HENRY SCHEIN INC (0001000228) (Filer)
8-K - HENRY SCHEIN INC (0001000228) (Filer)
SCHEDULE 13G/A - HENRY SCHEIN INC (0001000228) (Subject)
Henry Schein, Inc., (NASDAQ:HSIC) the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conference in December: Piper Sandler's Healthcare Conference at the Lotte New York Palace Hotel, New York, on December 2, 2025, at 9:00 a.m. Eastern time. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations. About Henry Schein, Inc. Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of pe
New embedded AI combines real-time insights and patient education, making it easier for clinicians to quickly identify and explain conditions, and guiding patients to make confident treatment decisions. VideaHealth, the leading dental AI platform, in collaboration with Henry Schein One, today announced the launch of the Impact Panel, a new enhancement within the Detect AI experience for Dentrix® and Dentrix Ascend® users. This product enhancement integrates VideaHealth's real-time AI findings and patient education tools directly into Henry Schein One's imaging workflows, enabling clinicians to communicate more clearly and guide patients toward confident treatment discussion and acceptance.
Q3 2025 GAAP diluted EPS of $0.84, compared to $0.78 GAAP diluted EPS in Q3 2024, and Q3 2025 non-GAAP diluted EPS of $1.38, compared to $1.22 non-GAAP diluted EPS in Q3 2024 Raises 2025 guidance for non-GAAP diluted EPS to $4.88 to $4.96 and sales growth to 3-4% to reflect third quarter results Announces value creation initiatives expected to deliver over $200 million of operating income improvement over the next few years Agreement reached to provide KKR the right to increase its HSIC stock ownership up to 19.9% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results
Evercore ISI upgraded Henry Schein from In-line to Outperform and set a new price target of $83.00
Stifel downgraded Henry Schein from Buy to Hold and set a new price target of $75.00
Robert W. Baird downgraded Henry Schein from Outperform to Neutral and set a new price target of $72.00
4 - HENRY SCHEIN INC (0001000228) (Issuer)
4 - HENRY SCHEIN INC (0001000228) (Issuer)
3 - HENRY SCHEIN INC (0001000228) (Issuer)
4 - HENRY SCHEIN INC (0001000228) (Issuer)
Q3 2025 GAAP diluted EPS of $0.84, compared to $0.78 GAAP diluted EPS in Q3 2024, and Q3 2025 non-GAAP diluted EPS of $1.38, compared to $1.22 non-GAAP diluted EPS in Q3 2024 Raises 2025 guidance for non-GAAP diluted EPS to $4.88 to $4.96 and sales growth to 3-4% to reflect third quarter results Announces value creation initiatives expected to deliver over $200 million of operating income improvement over the next few years Agreement reached to provide KKR the right to increase its HSIC stock ownership up to 19.9% Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its third quarter 2025 financial results before the stock market opens on Tuesday, November 4, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry Sc
Second-quarter 2025 GAAP diluted EPS of $0.70, compared to $0.80 GAAP diluted EPS in the second quarter of 2024 Second-quarter 2025 non-GAAP diluted EPS of $1.10, compared to $1.23 non-GAAP diluted EPS in the second quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Takes next steps in collaboration with KKR to pursue additional opportunities to create shareholder value Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the second quarter ended June
SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)
SC 13G - HENRY SCHEIN INC (0001000228) (Subject)
SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)
Mr. Bergman to Continue to Serve as Chairman of the Board Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that Stanley M. Bergman will retire as Chief Executive Officer (CEO) at the end of the year after 45 years at the Company, including more than 35 years as CEO. Mr. Bergman will continue to lead Henry Schein in his current role until his retirement and will remain as Chairman thereafter. The Board is commencing a formal search process in conjunction with a nationally recognized executive search firm and will consider internal and external candidates. "With the progress made advan
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein. In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Healt
Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca